Glimepiride induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A case report
Article Sidebar
Main Article Content
Abstract
The Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is an important cause of hyponatremia in hospitalized patients and can be caused by a variety of drugs. SIADH is a recognized side effect of 1st generation sulfonylurea (Chlorpropamide) due to its effect on vasopressin secretion. Here we described a 55-year-old woman with uncontrolled type 2 diabetes on glimepiride with SIADH presenting with anorexia, asthenia, and altered mental status. After the withdrawal of glimepiride, these symptoms were improved and sodium level returned to a normal value which demand monitoring of serum sodium level during treatment with glimepiride.
Downloads
Article Details
Copyright (c) 2022 Tanni AZ, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
SCHWARTZ WB, BENNETT W, CURELOP S, BARTTER FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957 Oct;23(4):529-42. doi: 10.1016/0002-9343(57)90224-3. PMID: 13469824.
Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967 May;42(5):790-806. doi: 10.1016/0002-9343(67)90096-4. PMID: 5337379.
Mather A, Burnett L, Sullivan DR, Stewart GD. Clinical biochemistry and metabolic medicine.In: Ralston SH, Penman ID, Strachan MWJ, Hobson EP (Eds). Davidson’s Principles and Practice of Medicine. 23rd Ed. China: Elsevier; 2018; 357-358.
Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med. 1985 Feb;102(2):164-8. doi: 10.7326/0003-4819-102-2-164. PMID: 3966753.
Castello LM, Baldrighi M, Panizza A, Bartoli E, Avanzi GC. Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the Emergency Department. Intern Emerg Med. 2017 Oct;12(7):993-1001. doi: 10.1007/s11739-016-1508-5. Epub 2016 Jul 21. PMID: 27444946.
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007 May 17;356(20):2064-72. doi: 10.1056/NEJMcp066837. PMID: 17507705.
Adachi H, Yanai H. Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion. Diabetes Metab. 2015 Apr;41(2):176-7. doi: 10.1016/j.diabet.2014.11.010. Epub 2015 Jan 2. PMID: 25559655.
Kulkarni O, Mulimani M, Bhavi V. Glimepiride and Syndrome of Inappropriate
Antidiuretic Hormone Secretion. IJSR. 2020; 9: 275.
Moug SJ, McKee RF, O'Reilly DS, Noble S, Boulton-Jones M. The perioperative challenge of nephrogenic diabetes insipidus: a multidisciplinary approach. Surgeon. 2005 Apr;3(2):89-94. doi: 10.1016/s1479-666x(05)80068-x. PMID: 15861943.
Bagshaw SM, Townsend DR, McDermid RC. Disorders of sodium and water balance in hospitalized patients. Can J Anaesth. 2009 Feb;56(2):151-67. doi: 10.1007/s12630-008-9017-2. Epub 2008 Dec 31. PMID: 19247764.
Shoback DM, Funk JL. Humoral Manifestation of Malignancy. In: Gardner DG, Shoback D (Eds). Greenspan’s Basic and Clinical Endocrinology. 10th ed. New York: Lange; 2018; 750-751.
Masharani U, German MS. Pancreatic Hormones and Diabetes Mellitus. In: Gardner DG, Shoback D (Eds). Greenspan’s Basic and Clinical Endocrinology. 10th ed. New York: Lange; 2018; 634-635.
Hagen GA, Frawley TF. Hyponatremia due to sulfonylurea compounds. J Clin Endocrinol Metab. 1970 Nov;31(5):570-6. doi: 10.1210/jcem-31-5-570. PMID: 5470213.
Murase T, Yoshida S. Mechanism of chlorpropamide action in patients with diabetes insipidus. J Clin Endocrinol Metab. 1973 Jan;36(1):174-7. doi: 10.1210/jcem-36-1-174. PMID: 4681880.
Yap PL, Harrower AD, Davidson NM, Strong JA. Glibenclamide and syndrome of inappropriate secretion of antidiuretic hormone. Br Med J. 1977 Apr 30;1(6069):1137. doi: 10.1136/bmj.1.6069.1137. PMID: 405069; PMCID: PMC1606687.
AMARYLR (glimepiride-tablets) is an oral blood-glucose-lowering drug of the sulfonylurea class. Sanofi-aventis U.S.LLC. Bridgewater. NJ08807. May, 2009.